Clinical Trials Logo

Clinical Trial Summary

Investigators aimed at comparing the impact on ovarian reserve of three usual-care management options of endometrioma, laparoscopic cystectomy (LC), hormonal treatment with daily dienogest (HT), or mere ultrasound control (UC). Ovarian reserve will be measured by the effect on the circulating levels of anti-Mullerian hormone (AMH). Secondary objectives will be effect on pelvic pain, other symptoms, sexual function, quality of life, progression in size of the endometrioma, impact on work productivity and activity impairment, and satisfaction with treatment. Participants will be followed by up to one year.


Clinical Trial Description

Investigators aimed at comparing the impact on ovarian reserve of three usual-care management options of endometrioma, laparoscopic cystectomy (LC), hormonal treatment with daily dienogest (HT), or mere ultrasound control (UC). Secondary objectives were the comparison of the effect on i) pelvic pain, including dysmenorrhea, non-menstrual pelvic pain, deep dyspareunia, or dyschezia, ii) other symptoms including menorrhagia, gastrointestinal symptoms different to dyschezia, or urinary symptoms; iii) quality of life as assessed by the EHP-30 questionnaire; iv) sexual functions, as assessed the female sexual function index (FSFI); v) progression in the size of the tumor in the case of the two non-surgical approaches; vi) impact on work productivity and activity impairment; vii) satisfaction in the patient. A prospective assessment will be performed on a cohort of women with endometrioma diagnosed by ultrasound from diagnosis for up to one year. The assignment to each management option will be performed under usual care conditions so that the selected option will result from the shared clinical decision of the clinician with the patient. The target population will be composed of Caucasian premenopausal women between 18-39 years with the diagnosis of endometrioma, one or more, with a diameter of up to 7 cm by endovaginal ultrasound. Body mass index comprised between 17-30 Kg/m2. Participants will be controlled at 3 months, 6 months and one year. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05637073
Study type Observational [Patient Registry]
Source University of Valencia
Contact Antonio Cano, MD
Phone +34629308479
Email antonio.cano@uv.es
Status Recruiting
Phase
Start date March 14, 2023
Completion date November 2, 2024

See also
  Status Clinical Trial Phase
Completed NCT01268930 - Comparison of Hemostatic Matrix and Bipolar Coagulation in Surgical Treatment of Endometriomas N/A
Completed NCT05323539 - Comparison of Thyroid Volumes in Patients With and Without Endometrioma N/A
Recruiting NCT04178876 - Comparison of Laparoscopic Endometrioma Stripping Versus Ethanol Sclerotherapy( CLESS) N/A
Recruiting NCT04151433 - Conservative Endometrioma Surgery N/A
Completed NCT01942122 - DLBS1442 for The Treatment of Pain in Patients Suspected Endometriosis Phase 2/Phase 3
Withdrawn NCT00999479 - Post Operative Continuous Active Combination Sex Steroids for the Prevention of Recurrent Endometrioma Formation N/A
Recruiting NCT03687398 - Genomic Maps of Endometrial Tissues of Patients With Endometriosis and Healthy Controls
Not yet recruiting NCT06377553 - PET/MRI for Evaluation of Endometriosis
Not yet recruiting NCT03788720 - Suture of the Ovary After Enucleation of Ovarian Endometrioma N/A
Completed NCT01982526 - Role of Anti Mullerian Hormone for Ovarian Reserve Determination of Preoperative and Postoperative Endometrioma Patients
Recruiting NCT05962775 - Ethanol Sclerotherapy Prior to ART N/A
Completed NCT03484546 - Optimum Menstrual Cycle Time for Endometrioma Excision
Completed NCT01808170 - Laparoscopic Ovarian Cystectomy of Endometrioma vs Deroofing and Ovarian Reserve N/A
Completed NCT06219044 - Evaluation of Ovarian Reserve and Recurrence Rate After DWLS Diode Laser OMA Vaporization N/A
Recruiting NCT03620838 - Endometrioma Per se Versus Treatment Related Reduction in Ovarian Reserve (ERROR-2 Trial)
Terminated NCT03571776 - Anti-mullerian Hormone (AMH) After Treatment of Endometriomas With Alcohol Sclerotherapy Versus Surgery: Clinical Trial N/A
Enrolling by invitation NCT02472873 - Efficacy of Aspiration and Sclerotherapy During Laparoscopy Using 95% Ethanol for the Treatment of Endometriomas N/A
Completed NCT04941833 - Desogestrel for the Preoperative Treatment of Endometrioma Compared With Placebo Phase 2/Phase 3
Completed NCT06274086 - Two-session Catheter-directed Sclerotherapy Using Ethanol for Endometrioma N/A
Not yet recruiting NCT04452123 - Endometrioma Treatment and Ovarian Function N/A